Antithrombotic therapy - ESC guidelines vs JCS guidelines

Circulation Journal

Volumn 74, Issue 12, 2010, Pages 2542-2545

  Inoue, Hiroshi ^a  

^a TOYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM;

ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 78649714207     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1074     Document Type: Article

References (32)

1. Sekikawa A, Satoh T, Hayakawa T, Ueshima H, Kuller LH. Coronary heart disease mortality among men aged 35-44 years by prefecture in Japan in 1995-1999 compared with that among white men aged 35-44 by State in the United States in 1995-1998: Vital statistics data in recent birth cohorts. Jpn Circ J 2001; 65: 887-892.
2. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol 2009; 137: 102-107.
3. European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369-2429.
4. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Executive summary. J Am Coll Cardiol 2006; 48: 854-906.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
6. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: Analysis of data from the general practice research database. Heart 2001; 86: 284-288.
7. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The An Ticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
8. Ohsawa M, Okayama A, Sakata K, Kato K, Itai K, Onoda T, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: An analysis from national surveys on cardiovascular diseases in 1980,1990 and 2000. J Epidemiol 2005; 15: 194-196.
9. Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: Analysis of 41,436 non-employee residents in Kurashiki-City. Circ J 2008; 72: 909-913.
10. Jeong JH. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 2005; 20: 26-30.
11. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Chen MF, et al. Atrial fibrillation prevalence, incidence and risk of stroke and all cause death among Chinese. Int J Cardiol 2010; 139: 173-180.
12. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Register of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
13. Wang TJ, Massaro JM, Levy D, Vasa RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003; 290: 1049-1056.
14. Nieuwlaat R, Capucci A, Camm AJ, Olsson B, Andersen D, Dacies DW, et al. Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on atrial fibrillation. Eur Heart J 2005; 26: 2422-2434.
15. Inoue H, Nozawa T, Hirai T, Goto S, Origasa H, Shimada K, et al. Sex-related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J-TRACE. Circ J 2010; 74: 650-654.
16. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, et al. Selecting patients with atrial fibrillation for anticoagulation: STROKE risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292.
17. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE for the ATRIA study group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51: 810-815.
18. Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006; 70: 651-656.
19. Ogawa S, Aizawa Y, Atarashi H, Inoue H, Okumura K, Kamakura S, et al. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008). Circ J 2008; 72(Suppl IV): 1581-1638 (in Japanese).
20. Research Group for Antiarrhythmic Drug Therapy. Atrial fibrillation and thromboembolism: A multicenter cooperative study. J Cardiol 1998; 31: 227-238 (in Japanese with English abstract).
21. Tomita F, Kohya T, Sakurai M, Kaji T, Yokoshiki H, Sato M, et al for Hokkaido Atrial Fibrillation Study Group. Prevalence and clinical characteristics of patients with atrial fibrillation: Analysis of 20,000 cases in Japan. Jpn Circ J 2000; 64: 653-658.
22. Inoue H, Atarashi H, Okumura K. Treatment and management of atrial fibrillation: Q & A, 2nd edn. Igaku-Shoin, Tokyo, 2009; 169 (in Japanese).
23. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36: 1588-1593.
24. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
25. Suzuki S, Yamashita T, Kato T, Fujino T, Sagara K, Sawada H, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007; 71: 761-765.
26. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447-451.
27. Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, et al. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS2 score 1. J Cardiovasc Electrophysiol 2010; 21: 501-507.
28. Lip GYH. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real life clinical practice. Thromb Haemost 2010; 103: 683-685.
29. You JHS, Chan EWH, Wong RSM, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-587.
30. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
31. Morgan CLI, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
32. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Olgdren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151